Drug profile · INN
cilostazol
CILOSTAZOL
cilostazol (CILOSTAZOL) is a phosphodiesterase 3a inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — cilostazol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 7
- Data quality
- 0.89
Quick answer
cilostazol (CILOSTAZOL) is a phosphodiesterase 3a inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 3A inhibitor
Primary target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is cilostazol?
cilostazol (CILOSTAZOL) is a phosphodiesterase 3a inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cilostazol?
CILOSTAZOL is a marketed brand name for cilostazol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cilostazol?
cilostazol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.